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Background: The exact cause of schizophrenia is not known, although several aetiological theories have been
proposed for the disease, including developmental or neurodegenerative processes, neurotransmitter abnormalities,
viral infection and immune dysfunction or autoimmune mechanisms. Growing evidence suggests that specific
cytokines and chemokines play a role in signalling the brain to produce neurochemical, neuroendocrine,
neuroimmune and behavioural changes. A relationship between inflammation and schizophrenia was supported by
abnormal cytokines production, abnormal concentrations of cytokines and cytokine receptors in the blood and
cerebrospinal fluid in schizophrenia. Since the neuropathology of schizophrenia has recently been reported to be
closely associated with microglial activation we aimed to determined whether spontaneous or LPS-induced
peripheral blood mononuclear cell chemokines and cytokines production is dysregulated in schizophrenic patients
compared to healthy subjects. We enrolled 51 untreated first-episode schizophrenics (SC) and 40 healthy subjects
(HC) and the levels of MCP-1, MIP-1a, IL-8, IL-18, IFN-g and RANTES were determined by Elisa method in cell-free
supernatants of PBMC cultures.
Results: In the simultaneous quantification we found significantly higher levels of constitutively and LPS-induced
MCP-1, MIP-1a, IL-8 and IL-18, and lower RANTES and IFNg levels released by PBMC of SC patients compared with
HC. In ten SC patients receiving therapy with risperidone, olanzapine or clozapine basal and LPS-induced
production of RANTES and IL-18 was increased, while both basal and LPS-induced MCP-1 production was
decreased. No statistically significant differences were detected in serum levels after therapy.
Conclusion: The observation that in schizophrenic patients the PBMC production of selected chemo-cytokines is
dysregulated reinforces the hypothesis that the peripheral cyto-chemokine network is involved in the
pathophysiology of schizophrenia. These preliminary, but promising data are supportive of the application of wider
profiling approaches to the identification of biomarker as diagnostic tools for the analysis of psychiatric diseases.
Background
Schizophrenia, a disease marked by distorted thinking,
hallucinations and reduced ability to feel normal emo-
tions, has long been associated with immunity, environ-
ment and heredity factors [1-3]. Recently, activation of
the inflammatory response system in schizophrenia was
suggested, and the link to inflammation might help to
explain why many patients with schizophrenia have
autoimmune diseases [4,5]. Immunological dysfunction
have been reported by several authors in schizophrenic
patients [6,8] and, although there are conflicting results,
most studies have independently focused on plasma
levels or mitogen-stimulated cytokine production, such
as interferon (IFN)-g, interleukin (IL)-2, IL-6 and tumor
necrosis factor (TNF)-a in peripheral blood mononuc-
lear cells (PBMC) and the Th1/Th2 imbalance [9-14].
However, apart from the pro-inflammatory cytokines,
chemokines play an important role in modulating brain
functions [15-19]. The bidirectional communication
between nervous and immune system cells might have
implications for psychiatric disorders. The cyto-chemo-
kine system and their receptors has been described in
neurons and glial cells as a major system regulating the
cross-talk between the central nervous system (CNS)
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the expression of chemokines and their receptors in
neuroinflammatory diseases, including multiple sclerosis,
Alzheimer’s disease and Parkinson’s disease [20-22].
These findings are consistent with the ability of chemo-
kines to control leukocyte infiltration into the central
nervous system during inflammation and development,
and to play a role as biomarkers of disease activity [23].
MCP-1 mediates the trans-endothelial migration of
inflammatory cells across the blood brain barrier (BBB),
modulates the local inflammatory response by forming che-
motactic gradients within the CNS and exerts a positive
regulatory effect on Th2 cell differentiation by inducing IL4
[24]. IL-8’s primary function is the induction of chemotaxis
in its target cells. Studies have demonstrated that circulating
levels of IL-8 might be increased in schizophrenic patients
[11], and high levels of IL-8 have been shown to reduce the
chance of good treatment responses to antipsychotic medi-
cation in schizophrenia [25]. The importance of IL-8 in
schizophrenia is underscored by the finding that patients
show increased IL-8 levels, as well as a correlation between
these levels and PANSS negative subscale N [11]. MIP-1a
acts by regulating the trafficking and activation state of
inflammatory cells e.g. macrophages, lymphocytes and NK
cells and no different levels of MIP-1a were detected in the
cerebrospinal fluid of schizophrenic patients and controls
[26]. RANTES is thought to promote leukocyte infiltration
in sites of inflammation and activate T cells [27,28]. IL-18, a
member of the IL-1 family, has potent pro-inflammatory
properties [29] and may stimulate the hypothalamic-
pituitary-adrenal axis and enhance sympathetic nerve sys-
tem activity, suggesting a pivotal role in psychological pro-
cesses and psychiatric disorders.
Keeping in mind the results of publications on cytokine
levels in patients with schizophrenia, in this study we
selected a number of additional cytokines and chemokines
which were less analyzed in other papers, and have ana-
lyzed the possibility that peripheral blood mononuclear
cells (PBMCs) of untreated first-episode schizophrenic
patients (SC) produce a broad range of proinflammatory
cytokines/chemokines and that schizophrenia may be, at
least in part, an illness of the cytokine system gone awry.
LPS-priming of PBMC cultures leads to the release of
multiple inflammatory cytokines and chemokines. This
preliminary, but promising study is supportive of the
application of short term cultures of PBMC as a valuable
and low cost method to assess a wider cyto-chemokine
profiles as diagnostic tools for the diagnosis of psychiatric
diseases.
Results
Chemokines and Cytokines production
Demographic data of studied subjects and clinic disabil-
ity measures are summarized in Table 1. There were no
significant differences in the male/female ratio (p =
0.660), or age (p = 0.131) between the SC and HC
groups. In order to investigate a possible involvement of
chemokines in schizophrenia, the production of MCP-1,
MIP-1a, IL-8, and RANTES by PBMC was evaluated.
Figure 1 shows the values of chemokines detected in
cell-free supernatants of PBMC from SC patients and
from HC subjects. Significantly higher levels of constitu-
tively produced MCP-1, MIP-1a and IL-8 and lower
RANTES levels were detected in SC patients compared
with HC, and the increment of LPS-induced production
was observed in both SC and HC group for all selected
molecules (p < 0.001). IL-8, MCP-1 and MIP-1a levels
released by LPS-stimulated PBMC from SC patients are
significantly higher, respect to levels released by LPS-
stimulated PBMC from HC subjects (p < 0.001), while
LPS-induced production of RANTES was lower in
PBMC of SC patients than in PBMC of HC subjects.
Both spontaneous and LPS-induced IL-18 production
are higher in SC compared to healthy controls; in fact,
IL-18 production in PBMC from SC patients was about
3 times higher than in PBMC from HC subjects. IFN-g
production in unstimulated PBMCs from SC patients
was lower than HC. After LPS-stimulation, IFNg levels
show an increment in both SC and HC subjects, but
higher levels were observed in HC subjects than in SC
(76.8 ± 34.3 vs 59.3 ± 8.2; p = 0.002) (Figure 2).
The relative variation of chemokine and cytokine
levels after LPS stimulation was calculated for each sub-
ject to analyze the different PBMCs responsiveness, to
underline the different cyto-chemokine production in
response to the same stimulus. A higher relative varia-
tion was observed in SC patients for RANTES (10.0)
and IFNg (7.7); lower relative variation was observed for
IL-18 (3.1), MCP-1 (1.5), IL-8 (1.3) and MIP-1a (0.8)
(Wilcoxon U test p < 0.001).
MCP-1, RANTES and IL-18 levels in atypical antipsychotic
short term treated SC patients
In order to determine whether short term atypical anti-
psychotic treatment influences MCP-1, RANTES and
IL-18 production we analyzed their levels in 10 SC
Table 1 Demographic data and clinic disability measures
of studied subjects
Variable HC (n = 40) SC (n = 51) p-value
Gender M/F 20/20 29/22 0.660
a
Age (years) 40.4 ± 10.3 35.7 ± 11.9 0.131
b
SAPS - 25.6 ± 11.2
SANS - 34.5 ± 8.71
a Chi-squared test.
b Mann-Whitney U test.
SAPS: Scale for the Assessment of Positive Symptoms.
SANS: Scale for the Assessment of Negative Symptoms.
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Page 2 of 9Figure 1 Comparison of chemokine production between SC patients and healthy controls. MCP-1, MIP-1a, IL-8 and RANTES release by
non-stimulated and LPS-stimulated PBMC (pg/ml/10
6 cells) from 40 healthy controls (HC) and 51 schizophrenic (SC) patients. Supernatants were
collected, stored at -80°C until analysis than measured for MCP-1, MIP-1a, IL-8 and IL-18 concentration using a commercial enzyme-linked
immunosorbent assay (ELISA). All samples for a given assay were analyzed in duplicate at the same time. The ELISA values (in duplicates for each
sample) have an error range lower than 10%. The variation coefficient of both inter-assay and intra-assay was <5%. Each data point represents
the release of MCP-1, MIP-1a, IL-8 and RANTES from each patient. Horizontal bars indicate group mean values.
Reale et al. BMC Neuroscience 2011, 12:13
http://www.biomedcentral.com/1471-2202/12/13
Page 3 of 9patients before and after therapy with risperidone (n =
4), olanzapine (n = 4) and clozapine (n = 2).
While basal and LPS-induced production of RANTES
and IL-18 was increased in all SC patients receiving
therapy with risperidone (n = 4), olanzapine (n = 4) and
clozapine (n = 2), the basal and LPS-induced MCP-1
production was decreased in SC patient receiving ther-
apy (p < 0.012 and p < 0.005 respectively) (Table 2).
The intra-individual analyses of cyto-chemokine levels
in short term therapy patients are in accord with the
demonstrated inter-individual results.
The serum levels of MCP-1, RANTES and IL-18 of
initially untreated and then medicated SC patients were
investigated, and non-statistically significant changes
were observed. The intra-individual analyses show that
in only one SC patients MCP-1 levels were increased, in
two SC patients RANTES was decrease, in two was
increased while in six patients no significant differences
were detected. IL-18 was very slowly increased in six SC
patients as shown in Figure 3. After 30 days of treat-
ment SAPS and SANS were unmodified or showed only
moderate improvement.
Discussion
Many authors have suggested that the in vitro secretion
of cytokines by peripheral blood cell preparations is the
most appropriate way to investigate the involvement of
cytokines in schizophrenia. In fact, circulating cytokine
l e v e l sf o u n di np l a s m aa n d / o rs e r u mm a yb ep r o d u c e d
by blood cells, endothelium, or may originate from the
Figure 2 Comparison of cytokine production between SC patients and healthy controls. IL-18 and IFN-g release by non-stimulated and
LPS-stimulated PBMC (pg/ml/10
6 cells) from 40 healthy controls (HC) and 51 schizophrenic (SC) patients. Supernatants were collected, stored at
-80°C until analysis than measured for IL-18 and IFN-g concentration using a commercial enzyme-linked immunosorbent assay (ELISA). All
samples for a given assay were analyzed in duplicate at the same time. The ELISA values (in duplicates for each sample) have an error range
lower than 10%. The variation coefficient of both inter-assay and intra-assay was <5%. Each data point represents the release of IL-18 and IFN-g
from each patient. Horizontal bars indicate group mean values.
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temic factors that are unrelated to psychiatric and neu-
rological disorders may influence circulating levels of
cytokines. Thus, measurement of the production of
cytokines by PBMC may better reflect their potential to
contribute to inflammation compared to assessment of
serum cytokine levels. The present study provides a
comparative evaluation of cyto-chemokine production
by PBMC from schizophrenic patients and from healthy
controls.
Abnormal regulation of cyto-chemokine activity may
contribute to pathophysiology and clinical manifesta-
tions in schizophrenic subjects. The evidence of recipro-
cal communication between immune and nervous
systems and the altered immunological state in psychia-
tric diseases have contributed to the ‘’cytokine hypoth-
esis’’. On the other hand cytokines, either directly or
indirectly from the periphery, are able to play a role in
signaling the brain to produce neurochemical, neuroen-
docrine, neuroimmune, and behavioral changes [30,31].
So far, the majority of studies in psychiatry have investi-
gated small cyto-chemokine subsets, mainly pro-
inflammatory molecules such as IL-1, IL-6, TNFa,
CXCL9 and CXCL11 under various in vitro conditions
with peripheral blood preparation, as well as in vivo in
various body fluid such as in plasma, serum, CSF and
urine of patients with schizophrenia [14,32,33]. Modified
production of cytokines, with conflicting data on circu-
lating serum levels of IL-6, TNFa has been reported.
Ganguli et al have demonstrated a positive association
of the serum IL-6 levels with duration of illness, while
Erbagci et al. have not found an altered plasma levels of
IL-6 and TNFa in drug-free schizophrenic patients on
acute exacerbation [34,35].
I nt h i ss t u d yw eh a v ea n a l y z e dt h ep r o d u c t i o no fa
number of additional cytokines and chemokines, pre-
viously studied [11,25,25,29], as well as some non-
previously studied in schizophrenia. LPS are potent and
pleitropic stimuli for cells of the immune system. Stimu-
lation of PBMC by LPS leads to the release of cytokines
and other inflammatory mediators. LPS activates nuclear
localization of transcription factor nuclear factor kB
(NF-kB) and subsequent activation of genes in the
proinflammatory pathways. On the basis of previous stu-
dies from our lab and other groups, LPS (10 mg/ml)
dosage and the incubation time have been shown to
induce the maximal stimulation for the PBMC release of
proinflammatory cytokines.
The present results demonstrate that production of
MCP-1, MIP-1a, IL-8 and IL-18 are significantly higher
in cell culture supernatants of PBMC from patients with
schizophrenia respect to age and gender-matched HC,
reinforcing the findings that schizophrenia is accompa-
nied by an activation of the monocyte-macrophage arm
Table 2 Cyto-chemokine production at baseline and after
1 month of therapy in SC patients












Basal 1071.5 ± 174.9 1161.2 ± 134.4 0.005
LPS 11755.4 ±
451.3
12125.0 ± 502.8 0.005
IL-18
Basal 62.9 ± 4.9 68.3 ± 5.7 0.005
LPS 298.0 ± 15.1 317.7 ± 14.2 0.005
Mean ± standard deviation of RANTES, MCP-1 and IL-18 levels (pg/ml)
released by non-stimulated and LPS-stimulated PBMC from 10 SC patients at
time of enrolment and after 1 months of treatment with atypical
antipsychotic drugs.
Figure 3 Serum levels of cyto-chemokine at baseline and after 1 month of therapy in SC patients. The serum levels of MCP-1, RANTES
and IL-18 in 10 SC patients before and after atypical antipsychotic short-term monotherapy. MCP-1, RANTES and IL-18 levels were assayed in
duplicate using a commercial ELISA a kit.
Reale et al. BMC Neuroscience 2011, 12:13
http://www.biomedcentral.com/1471-2202/12/13
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high level of IL-18, that induces the activation of Th1
cells, which may justify the reduced IFN-g release
observed in our schizophrenic patients when compared
to healthy subjects, in accordance with previous reports
that showed decreased IFNg production in PBMC from
schizophrenic patients [37]. Moreover, the lower levels
of RANTES, a selective attractant for memory T lym-
phocytes associated with the development of polarized
Th1-type cellular responses, fits well with the lower pro-
duction of IFNg in schizophrenic patients. The observed
decreased production of RANTES and increased levels
of MCP-1, a chemokine associated with the Th2-type
responses, in our SC subjects points to a blunted
production of related Th1 molecules and to an under-
activation of the Th2 system in schizophrenia, confirming
an alteration of the Th1/Th2 balance as hypothesized by
other authors [12,38]. RANTES and IFN-g production
that was lower in SC than HC, after LPS stimulation
showed greater improvement, while the other cyto-che-
mokine production that was higher in SC than HC
showed less improvement after LPS stimulation.
A weakly negative correlation was observed between the
relative variation of INF-g and the basal value of IL-18
(r = -0.215, p = 0.176) and between the relative variation
of RANTES and the basal value of MCP-1 (r = -0.174,
p = 0.178). Since the biological functions of cytokines are
physiologically interconnected, it might be expected that
there would also be an aberrant regulation of RANTES
and IFN-g production in SC patients, thus altered cyto-
chemokines production might represent a biological state
marker for PBMC in SC.
Atypical antipsychotics are becoming standard drugs
for the treatment of schizophrenia due to their less
adverse effects and the possible greater effectiveness for
the negative symptoms of the illness. Some studies often
have yielded dissimilar or conflicting results regarding
the effect that atypical antipsychotics may have on the
cytokine system [39], and associations between changes
in the levels of cytokines and the therapeutic response
have not been firmly established. Based on the informa-
tion available at present, atypical antipsychotics appear to
offer the same degree of safety in both short-term and
long-term treatment of schizophrenia. To speculate the
influence of antipsychotics on the cytokine system in SC
patients we have evaluated PBMC released and serum
levels of MCP-1, RANTES and IL-18 in SC patients after
short-term atypical antipsychotic treatment.
This preliminary study, including the relatively low
sample size, merely demonstrates that levels of IL-18
and RANTES are increased in PBMC from treated SC
patients, while MCP-1 levels are decreased. The com-
parison between the cyto-chemokine aberrations
observed in supernatants of PBMC from SC patients
after neuroleptic treatment and cyto-chemokine levels in
supernatants of PBMC from healthy controls are still
increasingly different.
In addition, we have observed that the antipsychotic
treatment did not significantly modulate IL-18, MCP-1
and RANTES serum levels. Discrepancies often arise
between data derived from levels of cyto-chemokines
produced in vitro by cultured PBMC and in vivo levels
in the serum due to the cytokines short half-life, and
high concentrations reached at the sites of release, but
having much lower concentrations in the blood.
The data presented here suggests that alteration of
these selected cytokines could be related to the disease
per se, but more SC patients must be analyzed to clarify
the effect of treatment with atypical antipsychotic drug
such as risperidone, olanzapine and clozapine on cyto/
chemokines production. Further studies are required to
better recognize the alteration in the cytokine networks
during antipsychotic treatment to clarify the relationship
with a clinical response. Our data confirmed and extend
the previous findings that altered inflammation-related
pathways characterize schizophrenia. The inflammatory
response connected with increased levels of IL-8,
MCP-1, MIP-1a and IL-18 released by PBMC may
demonstrate that physiological differences can indeed be
identified in the brain and also in the peripheral blood
of schizophrenic subjects.
Conclusions
Results of this preliminary but promising study suggest
that cyto-chemokine dysregulation may be involved in
the pathogenesis of schizophrenia, but immunological,
autonomic, and neuroendocrine abnormalities are
mutually dependent and mutually reinforcing factors.
In addition, our data could shed some light on the
possible relationship that exists between peripheral
levels of some cyto-chemokine and immunological state
in schizophrenic subjects. Although, these data need to
be confirmed through the analysis of greater sample
size, it remains to be established which are the mechan-
isms involved in this immune modulation, and which
a r es u p p o r t i v eo ft h ea p p l i cation of a wider profiling
approach to the identification of biomarkers (or clusters
of biomarkers) as diagnostic tools in schizophrenia.
Methods
Subjects
The sample included ninety-one subjects, consisting of
fifty-one (29 men and 22 women) unmedicated first-
episode schizophrenic patients (SC) and forty (20 men
and 20 women) education, nutritional and smoking
habit, sociodemographic status, lifestyle, frequency age-
matched healthy controls (HC). The control subjects
were neither related to one another nor to SC patients.
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jects were not considered suitable for the study (4 did
not meet the inclusion criteria and 2 for technical pro-
cedural reasons).
Two board-certified psychiatrists (C.U.P.; C.U.L.)
through the structured Clinical Interview gave their con-
sensus on the diagnosis, according to the DSM-IV cri-
teria [40,41] administered for the lifetime prevalence of
mental disorders. The psychopathological status of the
patients was assessed using the Positive and Negative
Syndrome Scale (PANSS) [42,43]. The mean SAPS sore
was 25.6 ± 11.2 and the mean SANS score was 34.5 ±
8.71.
Subjects with any other axis I disorders, as well as
those with alcohol and substance-related disorders, such
as major depression and bipolar disorders, earlier hospi-
talization, etc., were excluded. A complete medical his-
tory, including physical examination, laboratory test, and
electrocardiogram were obtained from patients and con-
trol subjects. Control’s and patient’sb l o o da n du r i n e
tests, such as SGOT, SGPT, hemoglobin, hematocrit,
serum electrolytes, blood urea, and creatinine, as well as
normal physical status needed to be within normal
ranges. To assess the inflammatory status (erythrocyte
sedimentation rate and C-reactive protein) all recruited
healthy controls and SC patients underwent the same
laboratory blood tests. Subjects having current
infections, allergies, or present and past history of
autoimmune disorders, on current medication such as
anti-inflammatory or antiviral agents that may affect
cytokines, were also excluded from the study. Neither
the schizophrenic patients nor the control subjects had
smoking habit (less than 4 cigarettes/day), suffered from
substance abuse/dependence, and all recruited subjects
were free of immunosuppressive medication.
Ten patients started atipycal antipsychotic monother-
apy treatment the day after recruitment and carried it
on during the 1 month hospital stay. The dose of neuro-
leptics was kept as low as possible in this study, but
doses were increased between week 1 and week 4, if
required (average dose range: risperidone 4.1-1.5 mg/d,
olanzapine 10-5.5 mg/d and clozapine 50-12.5 mg/d).
Treated patients were monitored for somatic illness
throughout the investigation period and no symptoms
of infection or of systemic somatic illness were present.
The study was conducted according to the declaration
of Helsinki and subsequent revision. All subjects (or
their caregivers) gave signed, informed consents to parti-
cipate in the study.
Cells sources and cultures
Venipuncture was performed in the morning between
08.00 and 10.00 h in order to avoid the effect of diurnal
variation, and peripheral blood samples were collected
into 4 ml endotoxin-free EDTA tubes (Vacutainer, Bec-
ton Dickinson, NJ, USA). Tubes were kept at room tem-
perature and transported to the laboratory for
processing within 1 h of collection. Peripheral blood
mononuclear cells (PBMC) were isolated by density-gra-
dient centrifugation through Ficoll-Hypaque (Pharma-
cia), suspended (10
6/ml) in RPMI 1640 medium (Sigma,
CA, USA), containing L-glutamine 1% and antibiotics
(penicillin 100 U/ml-streptomycin 100 ug/ml) with 10%
heat inactivated foetal calf serum (Sigma, CA, USA),
seeded in polypropylene tubes (Falcon, BD Lincoln Park,
N.J. 07035, U.S.A) and incubated at 37°C in 95% humi-
dified 5% CO2 cell culture incubator, with and without a
mitogenic stimulation with 10 μg/mL of bacterial lipo-
polysaccharide (LPS Escherichia coli 0127:B8; Sigma,
CA, USA). Cell viability in each culture was assessed by
Trypan blue die exclusion. All solutions were prepared
using pyrogen-free water and sterile polypropylene plas-
tic-ware and were free of detectable LPS (<0.1 EU/ml),
as determined by the Limulus amoebocyte lysate assay
(sensitivity limit 12 pg/ml; Associates of Cape Cod, MA,
USA). All reagents used were tested before use for
Mycoplasma contamination (minimum detection level
0.1 μg/ml) (Whittaker Bioproducts, Walkersville, MD,
USA) and found negative. The same batch of serum and
medium were used in all experiments. Each experiment
included three SC patients and at least one HC control.
After 24 h of incubation, samples were centrifuged at
400 × g for 10 min at room temperature, supernatants
collected and stored at -80°C until assays.
Serum sampling and measurement of MCP-1, RANTES
and IL-18 levels
The serum was obtained by blood centrifugation at 1500
× g for 7 min and kept frozen at -20°C until assay. MCP-
1, RANTES and IL-18 levels were assayed using a com-
mercial ELISA a kit (Endogen, Woburn, MA, U.S.A.).
In-vitro cytokine production: ELISA methods
Simultaneous determination of various cytokines and
chemokines were performed in PBMC culture superna-
tants. Cytokine concentration in culture supernatants,
stored at -80°C until assayed, was determined by a cyto-
kine-specific solid phase sandwich ELISA kit (Endogen,
Woburn, MA, U.S.A.) according to the manufacturers’
instructions. All steps were performed in duplicate and
at room temperature. Cytokine levels were then calcu-
lated plotting the O.D. of each sample against the stan-
dard curve. The RANTES, IL-8, IFNg and IL-18 assay
sensitivity was = 2 pg/ml, for MIP-1a assay sensitivity
was <5 pg/ml and for MCP-1 assay sensitivity was
<10 pg/ml. The intra and inter-assay reproducibility was
> 90%. Duplicate values that differed from the mean by
greater than 10% were considered suspect and were
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All quantitative variables were summarized as mean ±
standard deviation (SD). The qualitative variables were
summarized as frequency and percentage. The results were
reported separately for each groups (HC and SC). Normal
distribution of data was tested with the Shapiro-Wilk
W test and then statistical analysis was performed using
non-parametric tests. Chi-squared test and Mann-Whitney
U test were applied to evaluate the statistical differences of
gender distribution and age between two groups.
Significant differences in cyto-chemokine levels among
two groups (HC and SC) were evaluated using Mann-
Whitney U test, in basal and LPS stimulation conditions.
Relative variation of each cyto-chemokine levels between
basal and LPS stimulation conditions was evaluated as
(LPS value-basal value)/basal value and the Wilcoxon
U test was applied for assessing the variation between
basal and LPS stimulation conditions values. The same
statistical test was applied to evaluate the differences for
RANTES, MCP-1 and IL-18 between pre and post treat-
ment value. Spearman’s rho correlation coefficient (r)
was applied to assess the strength of relationship
between relative variation and basal levels of all cyto-
chemokines in for SC patients.
All statistical tests were evaluated at an alpha level of
0.05. Statistical analysis was performed using SPSS
®Advanced Statistical 11.0 software (SPSS Inc, Chicago,
Illinois, USA).
List of abbreviations
(HC): Healthy controls; (SC): schizophrenic patients; (LPS):
Lipopolysaccharides; PBMC (peripheral blood mononuclear cells)
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